📊 TSHA Key Takeaways
Is Taysha Gene Therapies, Inc. (TSHA) a Good Investment?
Taysha Gene Therapies exhibits severe operating losses (-$110.5M) on minimal revenue ($9.8M), burning $93.8M annually in free cash flow with limited runway despite a strong cash position of $319.8M. While early-stage biotech inherently operates at losses, the company's current trajectory shows no visible path to profitability and faces potential dilutive financing risk within 3-4 years at current burn rates.
Why Buy Taysha Gene Therapies, Inc. Stock? TSHA Key Strengths
- Strong balance sheet with $319.8M cash providing 3+ years operational runway
- Low leverage (Debt/Equity 0.20x) and minimal debt burden of $50.1M
- Revenue growth of +17.3% YoY demonstrates product traction and market demand
- Excellent liquidity (Current Ratio 12.23x) reduces financial distress risk
- Insider activity (5 Form 4 filings in 90 days) suggests management confidence
TSHA Stock Risks: Taysha Gene Therapies, Inc. Investment Risks
- Extreme operating losses (-$110.5M) and negative operating margin (-1130.6%) unsustainable long-term
- Annual free cash burn of $93.8M will exhaust cash reserves in 3.4 years without profitability inflection
- Revenue scale ($9.8M) is negligible relative to operating expenses, indicating early-stage commercialization challenges
- No gross profit visibility suggests weak unit economics or undisclosed cost structure
- Gene therapy development risk includes clinical trial failures, regulatory hurdles, and manufacturing scale-up challenges
Key Metrics to Watch
- Operating Cash Flow trend and path to cash flow breakeven
- Revenue growth rate acceleration (currently +17.3%) relative to expense management
- Cash runway depletion rate and timeline to next financing event
- Product pipeline advancement and clinical trial success rates
- Gross margin realization once manufacturing scales
Taysha Gene Therapies, Inc. (TSHA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.23x current ratio provides a solid financial cushion.
TSHA Profit Margin, ROE & Profitability Analysis
TSHA vs Healthcare Sector: How Taysha Gene Therapies, Inc. Compares
How Taysha Gene Therapies, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Taysha Gene Therapies, Inc. Stock Overvalued? TSHA Valuation Analysis 2026
Based on fundamental analysis, Taysha Gene Therapies, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Taysha Gene Therapies, Inc. Balance Sheet: TSHA Debt, Cash & Liquidity
TSHA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Taysha Gene Therapies, Inc.'s revenue has grown significantly by 291% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.36 indicates the company is currently unprofitable.
TSHA Revenue Growth, EPS Growth & YoY Performance
TSHA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$25.5M | $-0.09 |
| Q2 2025 | $1.1M | -$20.9M | $-0.09 |
| Q1 2025 | $2.3M | -$21.5M | $-0.08 |
| Q3 2024 | $1.8M | -$25.5M | $-0.10 |
| Q2 2024 | $1.1M | -$20.9M | $-0.09 |
| Q1 2024 | $3.4M | -$17.6M | $-0.10 |
| Q3 2023 | $4.7M | -$26.5M | $-0.65 |
| Q2 2023 | $2.4M | -$24.6M | $-0.38 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Taysha Gene Therapies, Inc. Dividends, Buybacks & Capital Allocation
TSHA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Taysha Gene Therapies, Inc. (CIK: 0001806310)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TSHA
What is the AI rating for TSHA?
Taysha Gene Therapies, Inc. (TSHA) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TSHA's key strengths?
Claude: Strong balance sheet with $319.8M cash providing 3+ years operational runway. Low leverage (Debt/Equity 0.20x) and minimal debt burden of $50.1M.
What are the risks of investing in TSHA?
Claude: Extreme operating losses (-$110.5M) and negative operating margin (-1130.6%) unsustainable long-term. Annual free cash burn of $93.8M will exhaust cash reserves in 3.4 years without profitability inflection.
What is TSHA's revenue and growth?
Taysha Gene Therapies, Inc. reported revenue of $9.8M.
Does TSHA pay dividends?
Taysha Gene Therapies, Inc. does not currently pay dividends.
Where can I find TSHA SEC filings?
Official SEC filings for Taysha Gene Therapies, Inc. (CIK: 0001806310) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TSHA's EPS?
Taysha Gene Therapies, Inc. has a diluted EPS of $-0.34.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TSHA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Taysha Gene Therapies, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TSHA stock overvalued or undervalued?
Valuation metrics for TSHA: ROE of -44.1% (sector avg: 15%), net margin of -1,115.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TSHA stock in 2026?
Our dual AI analysis gives Taysha Gene Therapies, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TSHA's free cash flow?
Taysha Gene Therapies, Inc.'s operating cash flow is $-93.1M, with capital expenditures of $738.0K. FCF margin is -960.1%.
How does TSHA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,115.3% (avg: 12%), ROE -44.1% (avg: 15%), current ratio 12.23 (avg: 2).